01417nas a2200229   4500000000100000008004100001653001400042653001500056653000800071653001200079100001900091700001800110700001200128700001800140700001200158245009200170856006000262300001300322490000600335050002200341520082400363       2013                            d10aTreatment10aNovel drug10aMDT10aleprosy1 aIllarramendi X1 aOliveira MLWD1 aSales A1 aCosta Nery JA1 aSarno E00aConsiderations on clinical trials of leprosy treatment: need of novel drug combinations  uhttp://www.future-science.com/doi/pdf/10.4155/cli.13.52  a617-635 0 v3  aILLARRAMENDI 20133 a<p>Considering that after 30 years of using multidrug therapy (MDT), leprosy eradication has still not been achieved, leprosy treatment must remain on the drug discovery agenda. Due to the complexities inherent in leprosy disease and the many methodological issues involved in clinical trials, the task of translating the bench findings into clinical practice has been arduous. While the effectiveness of reducing the currently recommended MDT remains controversial, a number of highly bactericidal antibiotics and immune-modulatory drugs have emerged as prospective candidates to improve patient adherence and quality of life, reduce adverse effects and prevent resistance. To replace the standard WHO-MDT, the new combination must be the shortest, simplest and, consequently, most affordable treatment possible.</p>